• Je něco špatně v tomto záznamu ?

A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting

M. Meckel, V. Kubíček, P. Hermann, M. Miederer, F. Rösch,

. 2016 ; 43 (11) : 670-678. [pub] 20160801

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023600

Radiolabeled bisphosphonates are commonly used in the diagnosis and therapy of bone metastases. Blood clearance of bisphosphonates is usually fast and only 30%-50% of the injected activity is retained in the skeleton, while most of the activity is excreted by the urinary tract. A longer blood circulation may enhance accumulation of bisphosphonate compounds in bone metastases. Therefore, a chemically modified macrocyclic bisphosphonate derivative with an additional human albumin binding entity was synthesized and pharmacokinetics of its complex was evaluated. The DOTA-bisphosphonate conjugate BPAMD was compared against the novel DOTAGA-derived albumin-binding bisphosphonate DOTAGA(428-d-Lys)M(BP) (L1). The ligands were labeled with (68)Ga(III) and were evaluated in in vitro binding studies to hydroxyapatite (HA) as well as to human serum albumin. The compounds were finally compared in in vivo PET and ex vivo organ distribution studies in small animals over 6h. Binding studies revealed a consistent affinity of both bisphosphonate tracers to HA. Small animal PET and ex vivo organ distribution studies showed longer blood retention of [(68)Ga]L1. [(68)Ga]BPAMD is initially more efficiently bound to the bone but skeletal accumulation of the modified compound and [(68)Ga]BPAMD equalized at 6h p.i. Ratios of femur epiphyseal plate to ordinary bone showed to be more favorable for [(68)Ga]L1 than for [(68)Ga]BPAMD due to the longer circulation time of the new tracer. Thus, the chemical modification of BPAMD toward an albumin-binding bisphosphonate, L1, resulted in a novel PET tracer which conserves advantages of both functional groups within one and the same molecule. The properties of this new diagnostic tracer are expected to be preserved in (177)Lu therapeutic agent with the same ligand (a theranostic pair).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023600
003      
CZ-PrNML
005      
20170908122037.0
007      
ta
008      
170720s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.nucmedbio.2016.07.009 $2 doi
035    __
$a (PubMed)27560354
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Meckel, Marian $u Institute of Nuclear Chemistry, Johannes-Gutenberg-University Mainz, Germany.
245    12
$a A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting / $c M. Meckel, V. Kubíček, P. Hermann, M. Miederer, F. Rösch,
520    9_
$a Radiolabeled bisphosphonates are commonly used in the diagnosis and therapy of bone metastases. Blood clearance of bisphosphonates is usually fast and only 30%-50% of the injected activity is retained in the skeleton, while most of the activity is excreted by the urinary tract. A longer blood circulation may enhance accumulation of bisphosphonate compounds in bone metastases. Therefore, a chemically modified macrocyclic bisphosphonate derivative with an additional human albumin binding entity was synthesized and pharmacokinetics of its complex was evaluated. The DOTA-bisphosphonate conjugate BPAMD was compared against the novel DOTAGA-derived albumin-binding bisphosphonate DOTAGA(428-d-Lys)M(BP) (L1). The ligands were labeled with (68)Ga(III) and were evaluated in in vitro binding studies to hydroxyapatite (HA) as well as to human serum albumin. The compounds were finally compared in in vivo PET and ex vivo organ distribution studies in small animals over 6h. Binding studies revealed a consistent affinity of both bisphosphonate tracers to HA. Small animal PET and ex vivo organ distribution studies showed longer blood retention of [(68)Ga]L1. [(68)Ga]BPAMD is initially more efficiently bound to the bone but skeletal accumulation of the modified compound and [(68)Ga]BPAMD equalized at 6h p.i. Ratios of femur epiphyseal plate to ordinary bone showed to be more favorable for [(68)Ga]L1 than for [(68)Ga]BPAMD due to the longer circulation time of the new tracer. Thus, the chemical modification of BPAMD toward an albumin-binding bisphosphonate, L1, resulted in a novel PET tracer which conserves advantages of both functional groups within one and the same molecule. The properties of this new diagnostic tracer are expected to be preserved in (177)Lu therapeutic agent with the same ligand (a theranostic pair).
650    _2
$a adsorpce $7 D000327
650    _2
$a zvířata $7 D000818
650    _2
$a kosti a kostní tkáň $x diagnostické zobrazování $x metabolismus $7 D001842
650    _2
$a bisfosfonáty $x chemie $x metabolismus $x farmakokinetika $7 D004164
650    _2
$a hydroxyapatit $x chemie $7 D017886
650    _2
$a radioizotopy galia $7 D005710
650    _2
$a heterocyklické sloučeniny monocyklické $x chemie $7 D006573
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a pozitronová emisní tomografie $7 D049268
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a sérový albumin $x metabolismus $7 D012709
650    _2
$a tkáňová distribuce $7 D014018
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kubíček, Vojtěch $u Department of Inorganic Chemistry, Charles University, Prague, Czech Republic.
700    1_
$a Hermann, Petr $u Department of Inorganic Chemistry, Charles University, Prague, Czech Republic.
700    1_
$a Miederer, Matthias $u Department of Nuclear Medicine, University Hospital, Mainz, Germany.
700    1_
$a Rösch, Frank $u Institute of Nuclear Chemistry, Johannes-Gutenberg-University Mainz, Germany.
773    0_
$w MED00008576 $t Nuclear medicine and biology $x 1872-9614 $g Roč. 43, č. 11 (2016), s. 670-678
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27560354 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170908122638 $b ABA008
999    __
$a ok $b bmc $g 1239281 $s 984513
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 43 $c 11 $d 670-678 $e 20160801 $i 1872-9614 $m Nuclear medicine and biology $n Nucl Med Biol $x MED00008576
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Možnosti archivace